226 related articles for article (PubMed ID: 27485078)
1. Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.
Xiong Z; Ampudia-Mesias E; Shaver R; Horbinski CM; Moertel CL; Olin MR
Immunotherapy; 2016 Sep; 8(9):1059-71. PubMed ID: 27485078
[TBL] [Abstract][Full Text] [Related]
2. CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy.
Xiong Z; Ampudia Mesias E; Pluhar GE; Rathe SK; Largaespada DA; Sham YY; Moertel CL; Olin MR
Clin Cancer Res; 2020 Jan; 26(1):232-241. PubMed ID: 31624103
[TBL] [Abstract][Full Text] [Related]
3. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor.
Rygiel TP; Karnam G; Goverse G; van der Marel AP; Greuter MJ; van Schaarenburg RA; Visser WF; Brenkman AB; Molenaar R; Hoek RM; Mebius RE; Meyaard L
Oncogene; 2012 Jun; 31(24):2979-88. PubMed ID: 22020332
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma antigen discovery--foundations for immunotherapy.
Azad TD; Razavi SM; Jin B; Lee K; Li G
J Neurooncol; 2015 Jul; 123(3):347-58. PubMed ID: 26045361
[TBL] [Abstract][Full Text] [Related]
5. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
6. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy.
Kretz-Rommel A; Qin F; Dakappagari N; Ravey EP; McWhirter J; Oltean D; Frederickson S; Maruyama T; Wild MA; Nolan MJ; Wu D; Springhorn J; Bowdish KS
J Immunol; 2007 May; 178(9):5595-605. PubMed ID: 17442942
[TBL] [Abstract][Full Text] [Related]
7. Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6.
Podnos A; Clark DA; Erin N; Yu K; Gorczynski RM
Breast Cancer Res Treat; 2012 Nov; 136(1):117-27. PubMed ID: 23053647
[TBL] [Abstract][Full Text] [Related]
8. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
9. Trials and tribulations of cancer immunotherapy: the dendritic cell vaccine shows promise in a phase I glioblastoma multiforme trial.
Gürsel DB; Schlaff CD; Boockvar JA
Neurosurgery; 2012 Dec; 71(6):N19-21. PubMed ID: 23160396
[No Abstract] [Full Text] [Related]
10. Immunological challenges for peptide-based immunotherapy in glioblastoma.
Mohme M; Neidert MC; Regli L; Weller M; Martin R
Cancer Treat Rev; 2014 Mar; 40(2):248-58. PubMed ID: 24064197
[TBL] [Abstract][Full Text] [Related]
11. The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
Reardon DA; Mitchell DA
Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787
[TBL] [Abstract][Full Text] [Related]
12. Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen.
Clark DA; Gorczynski RM; Blajchman MA
Transfusion; 2008 May; 48(5):814-21. PubMed ID: 18298594
[TBL] [Abstract][Full Text] [Related]
13. Overview of current immunotherapeutic strategies for glioma.
Calinescu AA; Kamran N; Baker G; Mineharu Y; Lowenstein PR; Castro MG
Immunotherapy; 2015; 7(10):1073-104. PubMed ID: 26598957
[TBL] [Abstract][Full Text] [Related]
14. Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response.
Erin N; Podnos A; Tanriover G; Duymuş Ö; Cote E; Khatri I; Gorczynski RM
Oncogene; 2015 Jul; 34(29):3860-70. PubMed ID: 25263452
[TBL] [Abstract][Full Text] [Related]
15. Identification of an expressed truncated form of CD200, CD200tr, which is a physiologic antagonist of CD200-induced suppression.
Chen Z; Chen DX; Kai Y; Khatri I; Lamptey B; Gorczynski RM
Transplantation; 2008 Oct; 86(8):1116-24. PubMed ID: 18946351
[TBL] [Abstract][Full Text] [Related]
16. Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.
Wang L; Liu JQ; Talebian F; El-Omrani HY; Khattabi M; Yu L; Bai XF
Eur J Immunol; 2010 Sep; 40(9):2569-79. PubMed ID: 20662098
[TBL] [Abstract][Full Text] [Related]
17. RNA aggregates harness the danger response for potent cancer immunotherapy.
Mendez-Gomez HR; DeVries A; Castillo P; von Roemeling C; Qdaisat S; Stover BD; Xie C; Weidert F; Zhao C; Moor R; Liu R; Soni D; Ogando-Rivas E; Chardon-Robles J; McGuiness J; Zhang D; Chung MC; Marconi C; Michel S; Barpujari A; Jobin GW; Thomas N; Ma X; Campaneria Y; Grippin A; Karachi A; Li D; Sahay B; Elliott L; Foster TP; Coleman KE; Milner RJ; Sawyer WG; Ligon JA; Simon E; Cleaver B; Wynne K; Hodik M; Molinaro AM; Guan J; Kellish P; Doty A; Lee JH; Massini T; Kresak JL; Huang J; Hwang EI; Kline C; Carrera-Justiz S; Rahman M; Gatica S; Mueller S; Prados M; Ghiaseddin AP; Silver NL; Mitchell DA; Sayour EJ
Cell; 2024 May; 187(10):2521-2535.e21. PubMed ID: 38697107
[TBL] [Abstract][Full Text] [Related]
18. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
Batich KA; Swartz AM; Sampson JH
Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice.
Gorczynski RM; Chen Z; Diao J; Khatri I; Wong K; Yu K; Behnke J
Breast Cancer Res Treat; 2010 Sep; 123(2):405-15. PubMed ID: 19953316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
